08:16 AM EST, 02/21/2025 (MT Newswires) -- Intra-Cellular Therapies ( ITCI ) reported a Q4 net loss Friday of $0.16 per diluted share, compared with a loss of $0.29 a year earlier.

Analysts polled by FactSet expected a loss of $0.07.

Total revenue for the quarter ended Dec. 31 was $199.2 million, up from $132.1 million a year earlier.

Analysts surveyed by FactSet expected $193.4 million.

Intra-Cellular shares were 0.8% higher in recent trading.